利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

9 条记录 (耗时 0.037 秒)

    FGFR INHIBITOR FOR USE IN THE TREATMENT OF HYPOPHOSPHATEMIC DISORDERS
    1.
    发明申请
    FGFR INHIBITOR FOR USE IN THE TREATMENT OF HYPOPHOSPHATEMIC DISORDERS 有权

    公开(公告)号：US20210308132A1

    公开(公告)日：2021-10-07

    申请号：US16005966

    申请日：2018-06-12

    申请人： Novartis AG

    发明人： Michaela Kneissel ,  Vito Guagnano ,  Diana Graus Porta ,  Simon Wöhrle

    IPC分类号： A61K31/506 ,  A61K45/06 ,  A61K33/42 ,  A61K33/06 ,  A61K38/17 ,  A61K38/29 ,  A61K31/59

    摘要： The present invention relates generally to 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimid-4-yl}-1-methyl-urea or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimid-4-yl}-1-methyl-urea or a pharmaceutically acceptable salt or solvate thereof for use in the treatment of X-linked hypophosphatemic rickets (XLH), autosomal dominant hypophosphatemic rickets (ADHR), autosomal recessive hypophosphatemic rickets (ARHR), tumor-induced osteomalacia, post-renal transplant hypophosphatemia, epidermal nevus syndrome, osteoglophonic dysplasia or McCune-Albright syndrome.

    FGFR inhibitor for use in the treatment of hypophosphatemic disorders
    2.
    发明授权
    FGFR inhibitor for use in the treatment of hypophosphatemic disorders 有权

    公开(公告)号：US10028955B2

    公开(公告)日：2018-07-24

    申请号：US15272633

    申请日：2016-09-22

    申请人： Novartis AG

    发明人： Michaela Kneissel ,  Vito Guagnano ,  Diana Graus Porta ,  Simon Wöhrle

    IPC分类号： A61K31/506 ,  A61K45/06 ,  A61K33/42 ,  A61K33/06 ,  A61K38/17 ,  A61K38/29 ,  A61K31/59

    摘要： The present invention relates generally to 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimid-4-yl}-1-methyl-urea or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimid-4-yl}-1-methyl-urea or a pharmaceutically acceptable salt or solvate thereof for use in the treatment of X-linked hypophosphatemic rickets (XLH), autosomal dominant hypophosphatemic rickets (ADHR), autosomal recessive hypophosphatemic rickets (ARHR), tumor-induced osteomalacia, post-renal transplant hypophosphatemia, epidermal nevus syndrome, osteoglophonic dysplasia or McCune-Albright syndrome.

    Pyrirnidinyl aryl urea derivatives being FGF inhibitors
    8.
    发明授权
    Pyrirnidinyl aryl urea derivatives being FGF inhibitors 失效
    吡咯烷基芳基脲衍生物是FGF抑制剂

    公开(公告)号：US08759517B2

    公开(公告)日：2014-06-24

    申请号：US13624320

    申请日：2012-09-21

    申请人： Novartis AG

    发明人： Guido Bold ,  Pascal Furet ,  Vito Guagnano

    IPC分类号： C07D239/48

    CPC分类号： C07D239/48 ,  C07D401/12

    摘要： The invention relates to heteroaryl aryl ureas of the formula IA, wherein the radicals and symbols have the meanings as defined herein, the use of such compounds in the treatment of protein kinase dependent diseases; to pharmaceutical preparations comprising said heteroaryl aryl ureas, to processes for the manufacture of such novel compounds and to methods of treatment comprising the use of such heteroaryl aryl ureas.

    摘要翻译： 本发明涉及式IA的杂芳基芳基脲，其中基团和符号具有本文定义的含义，这些化合物在治疗蛋白激酶依赖性疾病中的用途; 涉及包含所述杂芳基芳基脲的药物制剂，以及制备这些新化合物的方法和包括使用这种杂芳基芳基脲的治疗方法。

    Pyrimidinyl Aryl Urea Derivatives being FGF Inhibitors
    9.
    发明申请
    Pyrimidinyl Aryl Urea Derivatives being FGF Inhibitors 失效
    嘧啶基芳基脲衍生物是FGF抑制剂

    公开(公告)号：US20130030171A1

    公开(公告)日：2013-01-31

    申请号：US13624320

    申请日：2012-09-21

    申请人： Novartis AG

    发明人： Guido Bold ,  Pascal Furet ,  Vito Guagnano

    IPC分类号： C07D403/12 ,  C07D401/14 ,  C07D401/12 ,  C07D413/12 ,  C07D239/48

    CPC分类号： C07D239/48 ,  C07D401/12

    摘要： The invention relates to heteroaryl aryl ureas of the formula IA, wherein the radicals and symbols have the meanings as defined herein, the use of such compounds in the treatment of protein kinase dependent diseases; to pharmaceutical preparations comprising said heteroaryl aryl ureas, to processes for the manufacture of such novel compounds and to methods of treatment comprising the use of such heteroaryl aryl ureas.

    摘要翻译： 本发明涉及式IA的杂芳基芳基脲，其中基团和符号具有本文定义的含义，这些化合物在治疗蛋白激酶依赖性疾病中的用途; 涉及包含所述杂芳基芳基脲的药物制剂，以及制备这些新化合物的方法和包括使用这种杂芳基芳基脲的治疗方法。